Part 1 Basic Information

Name: Runting Yin

Address: Room 2507, School of Pharmacy, Jiangsu University, No. 301 Xuefu Road, Zhenjiang, Jiangsu 212013, China

Email: yinrt@ujs.edu.cn

Part 2 Personal Profile

Dr. Runting Yin is an Associate Professor and Master’s Supervisor at the School of Pharmacy, Jiangsu University. She received her Ph.D. in Pharmacy from China Pharmaceutical University and conducted postdoctoral research at Southeast University. From April 2016 to April 2017, she was a visiting scholar at the Ludwig Institute for Cancer Research, Uppsala University, working with Professor Carl-Henrik Heldin. Her research focuses on non-coding RNA-mediated regulation of tumor angiogenesis, PDGFR signaling and the tumor microenvironment, and the molecular mechanisms and development of anticancer therapeutics, including small molecules, peptides, recombinant proteins and monoclonal antibodies. She has served as principal investigator of a National Natural Science Foundation of China Young Scientists Fund project and a Jiangsu Provincial Natural Science Foundation Young Scientists Fund project, among other grants, and has participated in multiple collaborative research and drug-development projects. She has published 24 SCI-indexed papers (h-index: 17) and is named on several invention patents, including one transferred patent. She also serves on reviewer panels and as a guest editor for scholarly journals, including Current Medicinal Chemistry. Her teaching includes pharmacology, pharmaceutical molecular biology, laboratory courses and English-taught courses for international students.

Part 3 Education

2005.09–2010.06 | China Pharmaceutical University | Ph.D. in Pharmacy

2001.09–2005.07 | China Pharmaceutical University | B.S. in Bioengineering

Part 4 Work Experience

2021.04–Present | School of Pharmacy, Jiangsu University | Associate Professor, Master’s Supervisor

2017.11–2021.03 | Affiliated Hospital of Jiangsu University | Associate Professor

2016.04–2017.04 | Ludwig Institute for Cancer Research, Uppsala University, Sweden | Visiting Scholar (Host: Prof. Carl-Henrik Heldin)

2012.04–2017.10 | School of Pharmacy, Nantong University | Associate Professor

2010.07–2012.03 | Southeast University, Materials Science and Engineering (Center for New Drug Research) | Postdoctoral Researcher

Part 5 Research Interests

1. Molecular mechanisms and development of anticancer agents, including small molecules, peptides, recombinant proteins and monoclonal antibodies

2. Non-coding RNA regulation of tumor angiogenesis and therapeutic intervention targets

3. PDGFR signaling and molecular mechanisms of the tumor microenvironment

Part 6 Research Achievements

6.1 Research Projects

• NSFC Young Scientists Fund (81402189) | Principal Investigator

• Jiangsu Provincial Natural Science Foundation Young Scientists Fund (BK20130395) | Principal Investigator

• Talent Recruitment Project, Affiliated Hospital of Jiangsu University (JDFYRC2017009) | Principal Investigator

• Zhenjiang Key Research and Development Program (SH2020036) | Principal Investigator

• Jiangsu University High-level Talent Recruitment Project | Principal Investigator

• 10 NSFC General Program projects | Participant (ranking not provided)

• Major New Drug Creation project (1) | Participant (ranking not provided)

• Drug development project (1; clinical trial approval obtained) | Participant (ranking not provided)

6.2 Publications

1. Sun X, Lv W, Wang Y, Zhang X, Ouyang Z, Yin R, Wei Y. Mrgprb2 gene plays a role in the anaphylactoid reactions induced by Houttuynia cordata injection[J]. Journal of Ethnopharmacology, 2022, 289: 115053.(JCR Q1)

2. Yin R, Eger G, Sarri N, Rorsman C, Heldin C H, Lennartsson J. Dual specificity phosphatase (DUSP)-4 is induced by platelet-derived growth factor-BB in an Erk1/2-, STAT3- and p53-dependent manner[J]. Biochemical and Biophysical Research Communications, 2019, 519(3): 469-474.(JCR Q2; co-first author)

3. Yin R, Guo L, Gu J, Li C, Zhang W. Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesis[J]. International Journal of Biochemistry & Cell Biology, 2018, 97: 43-51.(JCR Q2)

4. Guo L, Yin R, Xu G, Gong X, Chang Z, Hong D, et al. Immunologic properties and therapeutic efficacy of a multivalent epitope-based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils[J]. Helicobacter, 2017, 22(6): e12428.(JCR Q2; co-first author)

5. Yin R, Guo L, Zhang J, Liu G, Yao W, Zhu H, et al. RGD and polyhistidine tumor homing peptides potentiates the action of human Maspin as an antineoplastic candidate[J]. Applied Microbiology and Biotechnology, 2016, 100(14): 6209-6218.(JCR Q2)

6. Yin R, Guo L, Zheng J, Zhang W. The pleiotropic effects of miRNAs on tumor angiogenesis[J]. Journal of Cellular Biochemistry, 2015, 116(9): 1807-1815.(JCR Q2)

7. Guo L, Yin R, Liu K, Lv X, Li Y, Duan X, et al. Immunological features and efficacy of a multi-epitope vaccine CTB-UE against H. pylori in BALB/c mice model[J]. Applied Microbiology and Biotechnology, 2014, 98(8): 3495-3507.(JCR Q2; co-first author)

6.3 Monographs and Textbooks

Yin R (Editorial Board Member). Pharmacology (Bilingual) [M]. Tianjin: Tianjin University of Science and Technology Press, 2013. (12th Five-Year Plan textbook)

6.4 Patents and Software Copyrights

1. Runting Yin (first inventor; transferred). 一种靶向性抗肿瘤血管抑制的融合蛋白及其构建方法与应用 [P]. Patent No. ZL201510179086.3. [Patent title retained in Chinese.]

2. Runting Yin (first inventor). 一种在大肠杆菌中生产抗血管剂RT-X的方法及其应用 [P]. Patent No. ZL201510179631.9. [Patent title retained in Chinese.]

3. Runting Yin (first inventor). miRNA-17-3p和miRNA-19b-1组合物及应用 [P]. Patent No. ZL201610161391.4. [Patent title retained in Chinese.]

4. Runting Yin (second inventor). 用于治疗卵巢癌的药物组合及其相关制剂 [P]. Patent No. ZL201811109716.X. [Patent title retained in Chinese.]